Analyst Consensus ?
ConsensusBuy33 ratings
Bullish2266.7%
Neutral927.3%
Bearish26.0%
Align Technology, Inc. · ALGN · FY2026 Q3 · Calendar Q4 2026
Align lowers 2026 guidance as consumer demand softens
The quarter provides mixed evidence for a durable growth case: record Clear Aligner shipments and multiple product and workflow initiatives support demand, while lower Q4 and FY2026 guidance, softer consumers, and ASP pressure argue for caution.
Reported After market closeNASDAQHealthcare
$10.91B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.80
Consensus $2.77
EPS surprise
+1.1%
Reported versus consensus
Reported revenue
$1.01B
Consensus $1.00B
Revenue surprise
+1.2%
Reported versus consensus
Market reaction
close-to-close (session unavailable)
Stock move
+1.1%
Event window
SPY move
+0.3%
Same window
Abnormal move
+0.8%
Stock minus SPY
Volume
1.4×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
ALGNSPY benchmark
Ask FN2 about ALGN FY2026 Q3
Transcript, numbers and history already loaded
Why did ALGN rise 1.1% after beating EPS estimates in FY2026 Q3?What changed in ALGN's guidance and outlook in FY2026 Q3?Give me the bull and bear case for ALGN after FY2026 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with Q2, the outlook weakened: guidance sentiment moved from maintained to lowered, Q3 Systems & Services revenue remained pressured by scanner mix and flexible acquisition models, and management added a CEO succession plan plus new NXT and Sports Guard initiatives.
Guidance delta
Management lowered Q4 and full-year 2026 guidance, citing softer consumer demand and ASP pressure.
Key takeaways
- Q3 revenue was $1.015 billion, with record Clear Aligner shipments.
- Systems & Services revenue declined as scanner mix shifted toward lower-priced configurations and flexible acquisition models.
- Management highlighted utilization, financing, digital workflows, and younger patients as growth levers.
- NXT 3D printing, Invisalign Sports Guard, and ART expand the product roadmap.
Management priorities
- Increase utilization among orthodontists, DSOs, and GP dentists.
- Expand iTero through leasing, rentals, and certified pre-owned models.
- Execute the CEO transition and complete the strategic and operating model review.
Follow ALGN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$153.62Previous close
$140Low
$284.72Average
$790High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Mizuho | Outperform | Outperform | Maintain | Oct 22, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Oct 21, 2026 |
| Baird | Neutral | Outperform | Downgrade | Oct 15, 2026 |
| Leerink Partners | Outperform | Outperform | Maintain | Oct 14, 2026 |
| Stifel | Buy | Buy | Maintain | Oct 9, 2026 |
| Evercore ISI Group | In Line | Outperform | Downgrade | Oct 5, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 23, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Apr 24, 2026 |
| Barclays | Overweight | Equal Weight | Upgrade | Mar 17, 2026 |
| HSBC | Buy | Hold | Upgrade | Feb 9, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Feb 5, 2026 |
| Jefferies | Hold | Buy | Downgrade | Oct 10, 2025 |
| Needham | Hold | Hold | Maintain | May 1, 2025 |
| B of A Securities | Underperform | Underperform | Maintain | Dec 13, 2024 |
| OTR Global | Mixed | Positive | Downgrade | Jun 4, 2024 |
| Goldman Sachs | Sell | Sell | Maintain | Feb 2, 2024 |
| Stephens & Co. | Overweight | Overweight | Maintain | Jul 28, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | May 4, 2022 |
| Wolfe Research | Outperform | Outperform | Maintain | Jul 29, 2021 |
| BNP Paribas | Outperform | Outperform | Maintain | Jul 8, 2021 |
| SVB Leerink | Outperform | Outperform | Maintain | Apr 29, 2021 |
| Berenberg | Buy | Hold | Upgrade | Apr 22, 2021 |
| Guggenheim | Buy | Buy | Maintain | Apr 18, 2019 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jul 26, 2018 |
| PiperJaffray | Overweight | Overweight | Maintain | May 24, 2018 |
| Leerink Swann | Outperform | Outperform | Maintain | May 24, 2018 |
| Deutsche Bank | Hold | Hold | Maintain | Dec 8, 2017 |
| Bank of America | Buy | Neutral | Upgrade | Jul 28, 2017 |
| Roth Capital | Buy | Buy | Maintain | Mar 23, 2016 |
| JMP Securities | Market Perform | Market Outperform | Downgrade | Jan 30, 2015 |
| Barrington Research | Outperform | Market Perform | Upgrade | Apr 7, 2014 |
| Cantor Fitzgerald | Buy | Hold | Upgrade | Oct 18, 2013 |
| Janney Capital | Buy | Buy | Maintain | Jan 29, 2013 |
Named analyst price targets
Upside is calculated against the persisted previous close $153.62. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Piper Sandler | Analyst unavailable | $205 | $150.5 | +33.4% | Oct 21, 2026 |
| Robert W. Baird | Analyst unavailable | $162 | $144.44 | +5.5% | Oct 15, 2026 |
| Leerink Partners | Analyst unavailable | $215 | $143.14 | +40.0% | Oct 14, 2026 |
| Stifel Nicolaus | Jonathan Block | $175 | $141.03 | +13.9% | Oct 9, 2026 |
| UBS | Analyst unavailable | $189 | $166.86 | +23.0% | Jul 23, 2026 |
| BMO Capital | Vik Chopra | $209 | $174.68 | +36.0% | Jul 8, 2026 |
| Morgan Stanley | Analyst unavailable | $188 | $190.67 | +22.4% | Apr 24, 2026 |
| Piper Sandler | Jason Bednar | $235 | $191.66 | +53.0% | Apr 21, 2026 |
| Barclays | Glen Santangelo | $200 | $187.68 | +30.2% | Feb 25, 2026 |
| HSBC | Sidharth Sahoo | $200 | $187.6 | +30.2% | Feb 9, 2026 |
| Evercore ISI | Elizabeth Anderson | $200 | $176.27 | +30.2% | Feb 5, 2026 |
| Stifel Nicolaus | Analyst unavailable | $210 | $161.3 | +36.7% | Feb 5, 2026 |
| Wells Fargo | Analyst unavailable | $200 | $173.75 | +30.2% | Feb 5, 2026 |
| Robert W. Baird | Analyst unavailable | $218 | $161.3 | +41.9% | Feb 5, 2026 |
| UBS | Analyst unavailable | $185 | $161.3 | +20.4% | Feb 5, 2026 |
| Piper Sandler | Analyst unavailable | $220 | $161.3 | +43.2% | Feb 5, 2026 |
| Mizuho Securities | Steven Valiquette | $200 | $171.49 | +30.2% | Jan 20, 2026 |
| Barclays | Analyst unavailable | $170 | $157.68 | +10.7% | Dec 8, 2025 |
| Stifel Nicolaus | Jonathan Block | $200 | $141.55 | +30.2% | Oct 30, 2025 |
| Evercore ISI | Analyst unavailable | $170 | $131.91 | +10.7% | Oct 30, 2025 |
| Piper Sandler | Jason Bednar | $200 | $131.91 | +30.2% | Oct 30, 2025 |
| Piper Sandler | Jason Bednar | $190 | $135.98 | +23.7% | Oct 23, 2025 |
| UBS | Analyst unavailable | $155 | $128.43 | +0.9% | Oct 16, 2025 |
| Mizuho Securities | Analyst unavailable | $170 | $125.79 | +10.7% | Oct 13, 2025 |
| Jefferies | Analyst unavailable | $140 | $131.87 | -8.9% | Oct 10, 2025 |
| Evercore ISI | Elizabeth Anderson | $160 | $131.12 | +4.2% | Oct 8, 2025 |
| Mizuho Securities | Analyst unavailable | $210 | $203.57 | +36.7% | Jul 31, 2025 |
| Morgan Stanley | Analyst unavailable | $154 | $142.5 | +0.2% | Jul 31, 2025 |
| Stifel Nicolaus | Jonathan Block | $275 | $207.66 | +79.0% | Oct 24, 2024 |
| Piper Sandler | Jason Bednar | $275 | $221.06 | +79.0% | Oct 24, 2024 |
| Leerink Partners | Michael Cherny | $235 | $207.66 | +53.0% | Oct 24, 2024 |
| Evercore ISI | Elizabeth Anderson | $250 | $207.66 | +62.7% | Oct 24, 2024 |
| Piper Sandler | Jason Bednar | $285 | $216.05 | +85.5% | Oct 17, 2024 |
| Stifel Nicolaus | Jonathan Block | $285 | $229.65 | +85.5% | Oct 11, 2024 |
| Goldman Sachs | Charles Perron-Piche | $225 | $231.04 | +46.5% | Oct 10, 2024 |
| Evercore ISI | Elizabeth Anderson | $270 | $234.85 | +75.8% | Oct 8, 2024 |
| Piper Sandler | Jason Bednar | $315 | $226.05 | +105.1% | Jul 25, 2024 |
| Robert W. Baird | Jeff Johnson | $325 | $251.6 | +111.6% | Jul 22, 2024 |
| Piper Sandler | Jason Bednar | $330 | $242.61 | +114.8% | Jun 21, 2024 |
| Piper Sandler | Jason Bednar | $375 | $305 | +144.1% | Apr 25, 2024 |
| Robert W. Baird | Jeff Johnson | $370 | $313.78 | +140.9% | Apr 25, 2024 |
| Stifel Nicolaus | Jonathan Block | $400 | $300.14 | +160.4% | Apr 18, 2024 |
| Stifel Nicolaus | Jonathan Block | $350 | $314.35 | +127.8% | Mar 15, 2024 |
| Piper Sandler | Jason Bednar | $355 | $320.69 | +131.1% | Mar 13, 2024 |
| Piper Sandler | Jason Bednar | $340 | $257.3 | +121.3% | Sep 9, 2022 |
| Stifel Nicolaus | Jonathan Block | $375 | $252.07 | +144.1% | Jul 26, 2022 |
| UBS | Analyst unavailable | $500 | $361.35 | +225.5% | Apr 26, 2022 |
| Piper Sandler | Analyst unavailable | $600 | $395.05 | +290.6% | Apr 21, 2022 |
| Jefferies | Brandon Couillard | $635 | $446.41 | +313.4% | Apr 3, 2022 |
| Leerink Partners | Richard Newitter | $770 | $621.87 | +401.2% | Jul 28, 2021 |
| Stephens | Chris Cooley | $700 | $627.19 | +355.7% | Jul 9, 2021 |
| BNP Paribas | Julien Ouaddour | $790 | $616.79 | +414.3% | Jul 8, 2021 |
Track every rating change on ALGN the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAlign Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to ten, who have mixed dentition (a combination of primary and permanent teeth).…
Historical context
All ALGN earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| GKOS Glaukos Corporation | FY2026 Q3 · Calendar Q4 2026 | +587.8% | +0.1% | Glaukos raises 2026 guidance after strong Epioxa and iDose growth |
| GEHC GE HealthCare Technologies Inc. | FY2026 Q3 · Calendar Q4 2026 | +11.7% | +6.6% | GE HealthCare raises 2026 outlook as margins expand |
| LH Labcorp Holdings Inc. | FY2026 Q3 · Calendar Q4 2026 | +3.0% | +8.8% | Labcorp raises 2026 outlook as specialty testing drives Q3 growth |
| BIIB Biogen Inc. | FY2026 Q3 · Calendar Q4 2026 | +31.7% | -3.4% | Biogen’s Q3 growth broadened beyond legacy MS franchise |
| GSK GSK plc | FY2026 Q3 · Calendar Q4 2026 | +10.5% | -4.3% | GSK Q3 2026: Specialty Medicines Drive Growth as Guidance Holds |
| BSX Boston Scientific Corporation | FY2026 Q3 · Calendar Q4 2026 | +2.0% | -5.8% | Boston Scientific: Cyber Incident Weighs on Q3; 2027 Outlook Softens |
Latest beats and misses
Who reports nextBeat on EPS
- F-PBFY2026 Q3 · October 28, 2026+19.5% EPS— move
- GKOSFY2026 Q3 · October 28, 2026+587.8% EPS+0.1% move
- GEHCFY2026 Q3 · October 28, 2026+11.7% EPS+6.6% move
- IEXFY2026 Q3 · October 28, 2026+4.0% EPS+2.3% move
- AONFY2026 Q3 · October 28, 2026+1.8% EPS+4.4% move
- LHFY2026 Q3 · October 28, 2026+3.0% EPS+8.8% move
Missed on EPS
- CPFY2026 Q3 · October 28, 2026-3.2% EPS-1.9% move
- LIIFY2026 Q3 · October 28, 2026-7.1% EPS-10.6% move
- EXRFY2026 Q3 · October 27, 2026-1.7% EPS+0.1% move
- NOWFY2026 Q3 · October 28, 2026-2.0% EPS-3.0% move
- CMGFY2026 Q3 · October 28, 2026-7.1% EPS+2.7% move
- GOOGFY2026 Q3 · October 28, 2026-11.3% EPS+1.6% move
Get the ALGN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-29T04:06:17.863421+00:00
- FN2 earnings calendar · 2026-10-29T01:23:20.584741+00:00
- Polygon adjusted daily market bars · 2026-10-29T13:10:41.118419+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-29T13:10:41.115624+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-29. For educational purposes only; not investment advice.